Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors.
M. S. Gordon
Research Funding - Exelixis
N. J. Vogelzang
Research Funding - Exelixis
P. Schoffski
Research Funding - Exelixis
A. Daud
Research Funding - Exelixis
A. I. Spira
No relevant relationships to disclose
B. A. O'Keeffe
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
T. Rafferty
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
Y. Lee
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
R. Berger
Research Funding - Exelixis
G. Shapiro
Research Funding - Exelixis